A Phase 4 interventional study of PROMUS Element Plus Coronary Stent System and Aspirin in Coronary Artery Disease, sponsored by Boston Scientific Corporation. Completed at 52 sites in United States. Per ClinicalTrials.gov, last updated 2018-07-26.
Sponsored by Boston Scientific Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aspirin in Coronary Artery Disease — 8 open to participants now, 9 under way, 1 of them phase 3. Aspirin · Coronary Artery Disease.
Among the 53 studies testing aspirin in Coronary Artery Disease, this one is the 11th largest by enrollment, is one of 2 that started in 2012, is one of 38 in phase 4, and was the 24th registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →8 of the 53 studies testing aspirin in Coronary Artery Disease are open now, in 6 countries. Recruiting first, the newest first:
Jilin University · Sites in China
Ages 18–85
Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o. · Sites in Poland
Ages 18+
Rajaie Cardiovascular Medical and Research Center · Sites in Iran, Islamic Republic of
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,681 is above the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 200 across the 53 interventional studies. Of the 35 that completed or were terminated, 15 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 53 have an industry lead sponsor. The 10 most frequent:
Boston Scientific Corporation is the lead sponsor of 528 studies on the registry; 40 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 57 (88%) have results posted.
46 studies in Coronary Artery Disease by Boston Scientific Corporation: none open now, none under way, none of them phase 3. Of 44 finished, 24 (55%) have results posted.
Among the 46 studies in Coronary Artery Disease by Boston Scientific Corporation, this one is the 2nd largest by enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2012, is one of 5 in phase 4, and was the 30th registered.
Boston Scientific Corporation’s Coronary Artery Disease studies by the year they started, since 2001.
2 of the studies testing aspirin in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT07796217Seoul National University Bundang HospitalComparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban Therapy | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies testing aspirin in Coronary Artery Disease, from their registry updates:
Among Boston Scientific Corporation’s 46 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice. Patients will have symptomatic heart disease or documented silent ischemia. This is a prospective, open-label consecutively-enrolling study. Clinical follow-up is through 5 years. Approximately 2,689 patients are to be enrolled in up to 65 centers in the United States.
The wide-spread use of drug-eluting stents (DES) has evolved as standard of care in de novo lesions. The PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients with symptomatic heart disease or documented silent ischemia due to de novo lesions in native coronary arteries ≥2.25 mm to ≤4.00 mm in diameter in lesions ≤34 mm in length. The proposed study will compile real-world clinical outcomes data for the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice.
Patients enrolled in this study are expected to follow antiplatelet therapy recommendations per American College of Cardiology (ACC)/American Heart Association (AHA)/Society for Cardiovascular Angiography and Interventions (SCAI) guidelines for percutaneous coronary intervention (PCI). Recommended medications include aspirin, which should be taken for 3 days prior to the procedure or as a peri-procedural loading dose and then continued indefinitely. Additionally, one of the following P2Y12 antagonists may be given in a peri-procedural loading dose and in a maintenance dose per physician discretion: clopidogrel, prasugrel, ticagrelor, or ticlopidine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects who receive the PROMUS Element everolimus-eluting coronary stent
Device: PROMUS Element Plus Coronary Stent System · Drug: Aspirin · Drug: P2Y12 antagonist
PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
Also known as: PROMUS Element stent
Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
Also known as: Acetyl salicylic acid
Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI. * Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily) * Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling) * Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided. * Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)
Also known as: PLAVIX (clopidogrel), TICLID (ticlopidine), EFFIENT (prasugrel), BRILINTA (ticagrelor)
Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients
Cardiac death or myocardial infarction rate at 12 months post implantation in PLATINUM-like patients (no acute myocardial infarction, graft stenting, chronic total occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial lesion, severe tortuosity, moderate/severe calcification, 3-vessel stenting, cardiogenic shock, left main disease, or acute/chronic renal dysfunction; lesion length ≤28 mm with reference vessel diameter ≥2.25 mm and \<2.5 mm, or lesion length ≤24 mm with diameter ≥2.5 mm and ≤4.25 mm); statistical testing will assess if rate meets the performance goal (3.2%)
Time frame: 12 months
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in PLATINUM-like Patients
ARC definite/probable ST rate in PLATINUM-like patients (no acute myocardial infarction, graft stenting, chronic total occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial lesion, severe tortuosity, moderate/severe calcification, 3-vessel stenting, cardiogenic shock, left main disease, or acute/chronic renal dysfunction; lesion length ≤28 mm with reference vessel diameter ≥2.25 mm and \<2.5 mm, or lesion length ≤24 mm with diameter ≥2.5 mm and ≤4.25 mm); statistical testing will assess if the annual ST rate increase after the first year meets the performance goal (1.0%)
Time frame: 12 months
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in All Patients
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Rate of Longitudinal Stent Deformation
Compression/elongation of a stent along its long axis resulting from interaction with an ancillary device (e.g., guide catheter) which catches the stent end or an internal stent strut; can occur with advancement or withdrawal of ancillary device. Under fluoroscopy, longitudinal compression usually results in increased strut density and elongation in decreased strut density ('pseudo-fracture'); both can occur in the same stent.
Time frame: Index Procedure
Major Adverse Cardiac Event Rate (MACE)
Composite of cardiac death, myocardial infarction, and target vessel revascularization
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Rate of Major Adverse Cardiac Events Related to the PROMUS Element Stent
Composite of cardiac death, myocardial infarction, and target vessel revascularization related to the PROMUS Element stent
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Myocardial Infarction (MI) Rate
New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin \>upper limit of normal(ULN); if no new Q-waves total CK levels \>3×ULN (peri-percutaneous coronary intervention \[PCI\]) or \>2×ULN (spontaneous) with elevated CK-MB or troponin \>3×ULN (peri-PCI) or \>2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5×ULN
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Rate of Myocardial Infarction (MI) Events Related to the PROMUS Element Stent
New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin \>upper limit of normal(ULN); if no new Q-waves total CK levels \>3×ULN (peri-percutaneous coronary intervention \[PCI\]) or \>2×ULN (spontaneous) with elevated CK-MB or troponin \>3×ULN (peri-PCI) or \>2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5×ULN
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Cardiac Death Rate
Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Rate of Cardiac Death Events Related to the PROMUS Element Stent
Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Target Vessel Revascularization (TVR) Rate
Target vessel revascularization is defined as any attempted or successfully completed percutaneous or surgical revascularization of a target vessel.
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Rate of Target Vessel Revascularization (TVR) Events Related to the PROMUS Element Stent
Target vessel revascularization is defined as any attempted or successfully completed percutaneous or surgical revascularization of a target vessel.
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Cardiac Death or Myocardial Infarction (MI) Rate
See individual descriptions of events.
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Rate of Cardiac Death or Myocardial Infarction Events Related to the PROMUS Element Stent
See individual descriptions of events.
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Target Vessel Failure (TVF) Rate
Target vessel failure (TVF) is defined as any revascularization of the target vessel, myocardial infarction (MI) related to the target vessel, or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether MI or death was related to the target vessel it will be considered TVF.
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Rate of Target Vessel Failure (TVF) Related to the PROMUS Element Stent
Target vessel failure (TVF) is defined as any revascularization of the target vessel, myocardial infarction (MI) related to the target vessel, or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether MI or death was related to the target vessel it will be considered TVF.
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
All Death Rate
All death includes cardiac death and non-cardiac death.
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Non-cardiac Death Rate
Non-cardiac death is defined as death not due to cardiac causes. Cardiac death is death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded.
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
All Death or Myocardial Infarction Rate
See description of individual events.
Time frame: ≤24 hours, 30 days, 180 days, annually through 5 years
Target Vessel Failure (TVF) Rate in PLATINUM-like Medically Treated Diabetic Patients
Any revascularization of the target vessel, myocardial infarction related to the target vessel, or death related to the target vessel. See individual components for descriptions. Statistical testing will determine if the rate meets the performance goal (12.6%)
Time frame: 12 Months
ARC ST Rate in PLATINUM-like Population.
Using the Academic Research Consortium (ARC) definition, the (definite/probable) stent thrombosis (ST) rate in the PLATINUM-like\* population will be analyzed. Statistical testing will be used to determine if the annual increase after the first year in ST rates observed in PLATINUM-like patients meets the performance goal of 1.0% (expected rate of 0.4% + a delta of 0.6%).
Time frame: Annually through 5 years
| Milestone | PROMUS Element Overall Population |
|---|---|
| Started | 2681 |
| Completed | 2681 |
| Not completed | 0 |
Cardiac death or myocardial infarction rate at 12 months post implantation in PLATINUM-like patients (no acute myocardial infarction, graft stenting, chronic total occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial lesion, severe tortuosity, moderate/severe calcification, 3-vessel stenting, cardiogenic shock, left main disease, or acute/chronic renal dysfunction; lesion length ≤28 mm with reference vessel diameter ≥2.25 mm and \<2.5 mm, or lesion length ≤24 mm with diameter ≥2.5 mm and ≤4.25 mm); statistical testing will assess if rate meets the performance goal (3.2%)
| percentage of patients | PROMUS Element |
|---|---|
| Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients | 1.78 |
ARC definite/probable ST rate in PLATINUM-like patients (no acute myocardial infarction, graft stenting, chronic total occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial lesion, severe tortuosity, moderate/severe calcification, 3-vessel stenting, cardiogenic shock, left main disease, or acute/chronic renal dysfunction; lesion length ≤28 mm with reference vessel diameter ≥2.25 mm and \<2.5 mm, or lesion length ≤24 mm with diameter ≥2.5 mm and ≤4.25 mm); statistical testing will assess if the annual ST rate increase after the first year meets the performance goal (1.0%)
| percentage of patients | PROMUS Element |
|---|---|
| Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in PLATINUM-like Patients | 0.3 |
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)
| percentage of patients | PROMUS Element |
|---|---|
| Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in All Patients | 0.7 |
Compression/elongation of a stent along its long axis resulting from interaction with an ancillary device (e.g., guide catheter) which catches the stent end or an internal stent strut; can occur with advancement or withdrawal of ancillary device. Under fluoroscopy, longitudinal compression usually results in increased strut density and elongation in decreased strut density ('pseudo-fracture'); both can occur in the same stent.
| stents | PROMUS Element |
|---|---|
| Rate of Longitudinal Stent Deformation | 2 |
Composite of cardiac death, myocardial infarction, and target vessel revascularization
| percentage of patients | PROMUS Element |
|---|---|
| Major Adverse Cardiac Event Rate (MACE) | 6.9 |
Composite of cardiac death, myocardial infarction, and target vessel revascularization related to the PROMUS Element stent
| percentage of patients | PROMUS Element |
|---|---|
| Rate of Major Adverse Cardiac Events Related to the PROMUS Element Stent | 4.7 |
New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin \>upper limit of normal(ULN); if no new Q-waves total CK levels \>3×ULN (peri-percutaneous coronary intervention \[PCI\]) or \>2×ULN (spontaneous) with elevated CK-MB or troponin \>3×ULN (peri-PCI) or \>2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5×ULN
| percentage of patients | PROMUS Element |
|---|---|
| Myocardial Infarction (MI) Rate | 1.1 |
New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin \>upper limit of normal(ULN); if no new Q-waves total CK levels \>3×ULN (peri-percutaneous coronary intervention \[PCI\]) or \>2×ULN (spontaneous) with elevated CK-MB or troponin \>3×ULN (peri-PCI) or \>2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5×ULN
| percentage of patients | PROMUS Element |
|---|---|
| Rate of Myocardial Infarction (MI) Events Related to the PROMUS Element Stent | 0.7 |
Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded
| percentage of patients | PROMUS Element |
|---|---|
| Cardiac Death Rate | 1.4 |
Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded
| percentage of patients | PROMUS Element |
|---|---|
| Rate of Cardiac Death Events Related to the PROMUS Element Stent | 1.3 |
Target vessel revascularization is defined as any attempted or successfully completed percutaneous or surgical revascularization of a target vessel.
| percentage of patients | PROMUS Element |
|---|---|
| Target Vessel Revascularization (TVR) Rate | 5.6 |
Target vessel revascularization is defined as any attempted or successfully completed percutaneous or surgical revascularization of a target vessel.
| percentage of patients | PROMUS Element |
|---|---|
| Rate of Target Vessel Revascularization (TVR) Events Related to the PROMUS Element Stent | 3.5 |
See individual descriptions of events.
| percentage of patients | PROMUS Element |
|---|---|
| Cardiac Death or Myocardial Infarction (MI) Rate | 2.3 |
See individual descriptions of events.
| percentage of patients | PROMUS Element |
|---|---|
| Rate of Cardiac Death or Myocardial Infarction Events Related to the PROMUS Element Stent | 1.8 |
Target vessel failure (TVF) is defined as any revascularization of the target vessel, myocardial infarction (MI) related to the target vessel, or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether MI or death was related to the target vessel it will be considered TVF.
| percentage of patients | PROMUS Element |
|---|---|
| Target Vessel Failure (TVF) Rate | 6.7 |
Target vessel failure (TVF) is defined as any revascularization of the target vessel, myocardial infarction (MI) related to the target vessel, or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether MI or death was related to the target vessel it will be considered TVF.
| percentage of patients | PROMUS Element |
|---|---|
| Rate of Target Vessel Failure (TVF) Related to the PROMUS Element Stent | 4.7 |
All death includes cardiac death and non-cardiac death.
| percentage of patients | PROMUS Element |
|---|---|
| All Death Rate | 2.3 |
Non-cardiac death is defined as death not due to cardiac causes. Cardiac death is death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded.
| percentage of patients | PROMUS Element |
|---|---|
| Non-cardiac Death Rate | 0.9 |
See description of individual events.
| percentage of patients | PROMUS Element |
|---|---|
| All Death or Myocardial Infarction Rate | 3.2 |
Any revascularization of the target vessel, myocardial infarction related to the target vessel, or death related to the target vessel. See individual components for descriptions. Statistical testing will determine if the rate meets the performance goal (12.6%)
| percentage of patients | PROMUS Element |
|---|---|
| Target Vessel Failure (TVF) Rate in PLATINUM-like Medically Treated Diabetic Patients | 3.26 |
Using the Academic Research Consortium (ARC) definition, the (definite/probable) stent thrombosis (ST) rate in the PLATINUM-like\* population will be analyzed. Statistical testing will be used to determine if the annual increase after the first year in ST rates observed in PLATINUM-like patients meets the performance goal of 1.0% (expected rate of 0.4% + a delta of 0.6%).
| percentage of participants | PROMUS Element Overall Population |
|---|---|
| ARC ST Rate in PLATINUM-like Population. | 0.0023 |
Collected over Serious and non-serious adverse events were collected from the point of subject enrollment through primary endpoint (12 months).. Non-serious events are listed at a 0.1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PROMUS Element | — | 780/2,681 (29.1%) | 5/2,681 (0.2%) |
| Event | PROMUS Element |
|---|---|
| ANGINA PECTORISCardiac disorders | 120/2681 |
| ANGINA UNSTABLECardiac disorders | 93/2681 |
| NON-CARDIAC CHEST PAINGeneral disorders | 78/2681 |
| CORONARY ARTERY DISEASECardiac disorders | 49/2681 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 46/2681 |
| PNEUMONIAInfections and infestations | 36/2681 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 33/2681 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 24/2681 |
| ATRIAL FIBRILLATIONCardiac disorders | 23/2681 |
| MYOCARDIAL INFARCTIONCardiac disorders | 22/2681 |
| Event | PROMUS Element |
|---|---|
| Myocardial InfarctionCardiac disorders | 5/2681 |
| Age, Continuous(years) | PROMUS Element |
|---|---|
| Mean | 63.7 ± 11.1 |
| Sex: Female, Male(Participants) | PROMUS Element |
|---|---|
| Female | 807 |
| Male | 1874 |
| Region of Enrollment(participants) | PROMUS Element |
|---|---|
| United States | 2681 |
| Cardiac History(participants) | PROMUS Element |
|---|---|
| History of CAD | 1625 |
| History of MI | 1409 |
| History of CHF | 275 |
| Stable Angina | 620 |
| Unstable Angina | 1347 |
| Silent Ischemia | 149 |
| History of PCI | 1159 |
| History of CABG | 457 |
| Cardiac Risk Factors(participants) | PROMUS Element |
|---|---|
| Smoking, Ever | 1600 |
| Current Diabetic Mellitus | 989 |
| Hyperlipidemia Requiring Medication | 2016 |
| History of Hypertension Requiring Medication | 2077 |
| Family History of CAD | 1625 |
| Lesion Characteristics: Target Lesion Vessel(lesions) | PROMUS Element |
|---|---|
| Left Anterior Descending Artery | 1339 |
| Circumflex Artery | 848 |
| Right Coronary Artery | 1165 |
| Left Main | 54 |
| Graft | 199 |
| Lesion Characteristics: Lesion Length(mm) | PROMUS Element |
|---|---|
| Mean | 17.0 ± 10.3 |
| Lesion Characteristics: Reference Vessel Diameter(mm) | PROMUS Element |
|---|---|
| Mean | 2.94 ± 0.51 |
1 further baseline measures are reported on the registry.
The record gives a start of May 2012, a primary completion of Aug 2014 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aspirin · Clopidogrel
Boston Scientific Corporation →